USPH Stock Cash Flow Statements

U.S. Physical Therapy Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

U.S. Physical Therapy Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-03-31

operating activities
net income including non-controlling interest	17,720,000	13,468,000	12,494,000	9,777,000	11,712,000	11,617,000	-1,293,000	12,222,000	14,864,000	11,427,000
adjustments to reconcile net income including non-controlling interest to net cash from operating activities:
depreciation and amortization	6,057,000	5,867,000	5,685,000	4,387,000	4,514,000	4,095,000	4,113,000	3,967,000	3,827,000	3,788,000	3,793,000	3,652,000	3,474,000	3,824,000	3,072,000	3,035,000	2,803,000	2,681,000	2,467,000	2,733,000	2,726,000	2,607,000	2,718,000	2,419,000	2,558,000	2,400,000	2,420,000	2,469,000	2,398,000	2,468,000	2,441,000	2,480,000	2,433,000	2,356,000	2,569,000	2,052,000	2,067,000	2,091,000	1,867,000	1,807,000	2,058,000	1,857,000	1,438,000	1,387,000	1,381,000	1,451,000	1,378,000	1,352,000	1,271,000	1,370,000	1,312,000	1,334,000	1,341,000	1,356,000	1,422,000	1,330,000	1,391,000	1,411,000	1,434,000	1,431,000	1,458,000	1,492,000	1,475,000	1,472,000	1,520,000	1,542,000	1,420,000	1,484,000	1,456,000	1,247,000	1,158,000	1,125,000	1,090,000
benefit from credit losses	1,995,000	1,848,000	1,847,000	1,721,000	1,717,000	1,627,000	1,572,000	1,525,000	1,563,000	1,512,000	1,356,000	1,336,000	1,551,000	1,305,000	1,383,000	1,358,000	1,364,000	1,200,000
equity-based awards compensation expense	2,117,000	1,771,000	1,986,000	1,921,000	1,919,000	1,997,000	1,785,000	1,859,000	1,786,000	1,806,000	1,802,000	1,802,000	1,814,000	1,846,000	1,587,000	2,875,000	1,754,000	1,651,000	2,592,000	1,936,000	1,503,000	1,886,000	1,723,000	1,704,000	1,830,000	1,728,000	1,486,000	1,516,000	1,556,000	1,381,000	1,622,000	1,065,000	1,065,000	1,280,000	1,214,000	1,264,000	1,263,000	1,221,000	1,216,000	990,000	907,000	863,000	858,000	735,000	651,000	722,000	731,000	639,000	513,000	546,000	496,000	547,000	541,000	528,000	519,000	444,000	373,000	341,000	272,000	306,000	360,000	415,000	384,000	414,000	417,000	397,000	421,000	339,000	341,000	356,000	323,000	257,000	222,000
amortization of debt issue costs	104,000	106,000	105,000	107,000	104,000	106,000
change in deferred income taxes	2,037,000	5,242,000	4,760,000	-165,000	-1,173,000	1,943,000	-903,000	3,594,000
change in revaluation of put-right liability	339,000	404,000	-54,000	-167,000	223,000	80,000	-2,926,000	145,000	50,000	149,000	776,000
change in fair value of contingent earn-out consideration			-5,113,000	1,898,000	4,046,000	-612,000	1,747,000			698,000	-520,000
equity of earnings in unconsolidated affiliate	-401,000	-393,000	-264,000	-231,000	-248,000	-271,000	-149,000
loss on sale of fixed assets					46,000	5,000										7,000				-83,000									40,000	54,000		18,000	32,000	33,000
loss on sale of a partnership	0	123,000
changes in operating assets and liabilities:
patient accounts receivable,net
accounts receivable - other
other current and long term assets
accounts payable and accrued expenses
other long-term liabilities
net cash from operating activities	34,861,000	-4,675,000	19,409,000	22,120,000	28,992,000	4,419,000	26,835,000	16,364,000	27,430,000	11,349,000	17,299,000	13,727,000	15,862,000	11,649,000	15,905,000	24,945,000	17,882,000	17,674,000	25,393,000	26,246,000	31,976,000	16,380,000	15,984,000	17,843,000	15,058,000	13,563,000	19,000,000	23,384,000	15,090,000	15,531,000	15,695,000	18,640,000	8,020,000	14,171,000	9,022,000	8,664,000	18,653,000	14,711,000	16,220,000	3,019,000	16,368,000	7,772,000	17,364,000	3,690,000	15,936,000	8,143,000	15,863,000	4,853,000	9,899,000	10,383,000	13,796,000	5,171,000	12,062,000	7,752,000	7,146,000	5,695,000	6,739,000	11,242,000	6,511,000	6,029,000	6,427,000	9,826,000	8,258,000	6,433,000	9,400,000	10,813,000	6,059,000	3,900,000	6,617,000	5,308,000	1,722,000	5,400,000	4,981,000
investing activities
purchase of fixed assets	-3,251,000	-2,579,000	-2,489,000	-2,523,000	-2,336,000	-1,838,000	-2,220,000	-2,551,000	-2,464,000	-2,059,000	-958,000	-2,721,000	-2,041,000	-2,528,000	-2,205,000	-2,695,000	-1,693,000	-1,608,000	-2,145,000	-866,000	-1,874,000	-2,754,000	-2,761,000	-2,552,000	-2,379,000	-2,497,000	-1,886,000	-2,037,000	-1,866,000	-1,404,000	-1,519,000	-2,331,000	-1,658,000	-1,587,000	-2,640,000	-2,167,000	-1,715,000	-1,738,000	-1,454,000	-1,419,000	-1,255,000	-1,780,000	-1,283,000	-849,000	-1,179,000	-1,064,000	-1,124,000	-1,270,000	-1,286,000	-1,005,000	-1,047,000	-896,000	-794,000	-944,000	-624,000	-860,000	-1,003,000	-1,082,000	-1,000,000	-588,000	-594,000	-992,000	-728,000	-1,562,000	-1,126,000	-1,076,000	-1,169,000	-928,000	-1,187,000	-745,000	-1,318,000	-784,000	-1,480,000
purchase of majority interest in businesses, net of cash acquired	-2,679,000	-4,211,000	-91,891,000	-2,501,000	-22,724,000	-15,971,000	-3,588,000	-14,954,000	-2,244,000	-5,796,000	-41,215,000	-6,774,000	-557,000	-11,242,000	-64,234,000	-2,187,000	-8,655,000	-11,747,000	-8,585,000	-3,689,000	0	-11,633,000
purchase of redeemable non-controlling interest, temporary equity	-7,520,000	-907,000	-1,095,000	-727,000	-3,528,000	-2,702,000	-3,182,000	0	-2,626,000	-5,178,000	-891,000	-5,448,000	-6,437,000	-2,211,000	-13,549,000	-5,380,000			-17,298,000	-699,000	-536,000	-1,852,000	-2,952,000	-3,646,000
purchase of non controlling interest, permanent equity			-248,000	-229,000	-29,000	-498,000
proceeds from the sale of non-controlling interest, permanent equity
proceeds from the sale of partnership interest - redeemable non-controlling interest, temporary equity	0	15,000
repayment of notes receivable related to redeemable non-controlling interest
proceeds from the sale of partnership
distributions from unconsolidated affiliate	354,000	310,000	242,000	306,000	165,000	367,000	149,000	179,000	257,000	245,000	39,000	672,000	416,000	132,000
other	184,000	44,000	778,000	-328,000	156,000	88,000	271,000			125,000	-95,000	0	-81,000	93,000	-121,000	-20,000	-5,000	12,000	278,000			129,000	-24,000	99,000	9,000	12,000	209,000	6,000	-104,000	56,000	581,000	0			0	557,000	-557,000	1,000			45,000	132,000	44,000	1,000		-310,000	0	33,000					1,208,000	-180,000	-217,000	-374,000		-13,000	-138,000	-24,000													-54,000
net cash (used in) investing activities	-12,706,000	-6,628,000
financing activities
proceeds from revolving facility	56,500,000	17,000,000					0
payments on revolving facility							0
distributions to non-controlling interest, permanent and temporary equity	-7,044,000	-3,653,000	-3,312,000	-3,081,000	-5,158,000	-3,160,000	-4,323,000	-3,346,000	-5,134,000	-3,297,000	-3,588,000	-4,558,000	-3,491,000	-3,711,000	-2,601,000
cash dividends paid to shareholders			-6,642,000	-6,634,000			-6,445,000	-6,445,000			-5,331,000	-5,331,000			-4,831,000	-4,906,000			0	0			-3,832,000	-3,832,000			-2,918,000	-2,918,000				-5,031,000
payments on term loan	-1,875,000	-3,750,000	0	-1,875,000	-937,000	-938,000	-937,000			-938,000
principal payments on notes payable	-1,155,000	-473,000	-1,226,000	-613,000	-721,000	-392,000	-1,526,000	-1,788,000	-664,000	-422,000	-434,000	-158,000	-6,000	-332,000	-237,000	-455,000	-4,062,000	-145,000	-337,000	-386,000	-200,000	-114,000	-24,000	-352,000	-575,000	-482,000	-1,750,000	-396,000	-1,075,000	-823,000	-451,000	1,000	-75,000	-702,000	-208,000	-59,000	-283,000	-250,000
net cash (used in) financing activities
net (decrease) in cash and cash equivalents	-5,097,000	-2,179,000
cash and cash equivalents - beginning of period	0	41,362,000	0	0	0	152,825,000	0	0	0	31,594,000	0	0	0	28,567,000	0	0	0	32,918,000	0	0	0	23,548,000	0	0	0	23,368,000	0	0	0	21,933,000	0	0	0	20,047,000	0	0	0	15,778,000	0	14,271,000								11,671,000
cash and cash equivalents - end of period	-5,097,000	39,183,000	-75,597,000	4,048,000	-19,379,000	132,290,000	5,140,000	-13,053,000	128,133,000	32,605,000	-6,320,000	-10,658,000	24,343,000	24,229,000	9,379,000	-1,231,000	2,482,000	17,937,000	2,789,000	-13,426,000	-45,996,000	89,551,000	-4,308,000	-7,003,000	14,621,000	20,238,000	-8,873,000	5,093,000	7,335,000	19,813,000	4,515,000	-2,824,000	-4,912,000	25,154,000	5,023,000	-5,429,000	1,247,000	19,206,000										10,284,000																									15,861,000
supplemental disclosures of cash flow information
cash paid during the period for:
income taxes	2,474,000	7,359,000	-927,000	827,000	4,565,000	367,000	2,195,000	1,490,000	799,000	442,000	86,000	3,005,000	4,443,000	81,000	1,437,000	3,810,000	6,905,000	62,000	3,256,000	4,364,000	-185,000	242,000	398,000	5,119,000	4,026,000	313,000	226,000	1,474,000	4,542,000	2,941,000	484,000	543,000	7,430,000	86,000	533,000	4,538,000	3,248,000	2,265,000	2,560,000	1,275,000	1,333,000	4,685,000	2,993,000	242,000	-291,000	2,403,000	1,822,000	177,000	1,161,000	1,314,000	3,310,000	576,000	1,156,000	4,514,000	2,752,000	615,000	1,636,000	1,381,000	4,368,000	419,000	1,499,000	1,874,000	3,328,000	1,744,000	128,000	808,000	1,946,000	1,518,000	1,405,000	1,391,000	2,576,000	109,000	256,000
interest paid	2,478,000	2,205,000	1,579,000	1,922,000	1,864,000	1,844,000	1,663,000	2,981,000	2,634,000	1,377,000	3,528,000	840,000	794,000	525,000
non-cash investing and financing transactions during the period:
purchase of businesses - seller financing portion							-45,000	1,500,000	0	360,000	750,000	450,000	74,000	300,000	1,250,000	1,250,000	250,000	300,000	325,000	496,000	0	300,000	0
fair market value of initial contingent consideration related to purchase of businesses	1,800,000	1,259,000
offset of notes receivable associated with purchase of redeemable non-controlling interest				552,000	0	75,000
notes payable related to purchase of non-controlling interest, temporary equity
notes payable related to purchase of redeemable non-controlling interest, temporary equity	0	89,000	5,000				70,000	396,000	10,000	611,000	0	126,000	702,000	246,000									0
notes receivable related to sale of redeemable non-controlling interest, temporary equity				1,673,000	87,000	315,000	1,072,000
notes receivable related to the sale of non-controlling interest, permanent equity			0	39,000	0	243,000	61,000
gain on change in fair value of contingent earn-out consideration		-4,822,000
increase in patient accounts receivable		-7,341,000	3,524,000	-3,760,000	14,000	-5,124,000	-230,000	-74,000	658,000	-5,999,000	-2,694,000	-126,000	-2,783,000	-4,676,000	-1,904,000	-2,188,000	-637,000	-4,688,000				3,209,000	1,795,000	-3,215,000	-58,000	-4,898,000	-2,342,000	1,049,000	641,000	-2,782,000	-1,533,000	2,092,000	-2,464,000	-1,542,000	-727,000	-99,000	-264,000	-2,185,000	-695,000	-2,185,000	-436,000	-510,000	-1,440,000	-3,002,000	-2,071,000	-776,000	887,000	-3,429,000	-365,000	315,000	566,000	-2,179,000	-1,336,000	-83,000	46,000	-3,774,000	-553,000	-1,557,000	-476,000	-1,583,000				-503,000									-1,218,000
decrease (increase) in accounts receivable - other		774,000																220,000																													-70,000	74,000
increase in other current and long term assets		-6,209,000	990,000	-166,000	-1,209,000	-433,000	-2,686,000
decrease in accounts payable and accrued expenses		-14,229,000				-6,678,000																																						-5,241,000				-2,460,000		-1,016,000									-2,028,000	-58,000			-1,066,000	-324,000
increase in long term liabilities		-1,284,000
proceeds from sale of partnership		700,000
net cash from financing activities		9,124,000	-153,000	-12,230,000	-20,080,000	-4,490,000	-13,281,000	-12,476,000	107,682,000	2,343,000	19,772,000	-10,047,000	16,077,000	-43,000	73,352,000	-15,293,000	4,772,000	-19,452,000	5,684,000	-34,836,000	-75,816,000	65,546,000	-14,264,000	-18,122,000	20,174,000	-12,063,000	-25,844,000				-6,854,000	-19,063,000	6,721,000	8,131,000	8,157,000	-11,512,000	-15,770,000	4,836,000	-7,784,000	5,482,000	-16,148,000	-1,564,000	-7,193,000	3,964,000	22,482,000	-4,942,000	-8,846,000	187,000	-6,174,000	-6,965,000	-8,149,000	-2,169,000	-9,455,000	4,873,000	7,673,000	-3,336,000	3,181,000	-7,312,000	-10,285,000	8,278,000	-5,362,000	-9,833,000	-8,194,000	-3,913,000	418,000	-7,830,000	2,900,000	1,353,000	-6,421,000	10,417,000	-1,091,000	-1,392,000	-1,788,000
purchase of redeemable non-controlling interest, temporary equity, recorded in accrued liabilities		6,672,000
notes receivable related to sale of redeemable non-controlling interest		646,000
offset to notes receivable associated with purchase of redeemable non-controlling interest		180,000
dividends payable to usph shareholders		6,836,000				6,630,000				5,617,000				5,327,000				4,514,000
gain on sale of clinics and fixed assets							272,000	-169,000
impairment of goodwill and other intangible assets
impairment of assets held for sale
increase in accounts receivable - other			-5,588,000	1,391,000	1,634,000	-3,985,000	1,275,000	-1,546,000	711,000	-796,000	4,244,000	-1,689,000	-717,000	-2,145,000	-800,000							-1,752,000	-1,493,000	1,462,000	-1,973,000	-495,000	2,867,000	-1,020,000	-2,085,000	-849,000	1,714,000	-1,330,000	291,000	-3,697,000								18,000
decrease (increase) in accounts payable and accrued expenses
increase in other long-term liabilities			-816,000	-1,137,000	496,000	52,000		292,000			2,979,000	2,459,000			-5,603,000	209,000	2,345,000	-1,743,000
proceeds on sale of non-controlling interest, permanent equity			0	0	3,000	23,000	72,000
proceeds on sale of partnership interest - redeemable non-controlling interest, temporary equity						67,000	60,000
proceeds on sale of partnership interest, clinics and fixed assets
net cash from investing activities			-94,853,000	-5,842,000	-28,291,000	-20,464,000	-8,414,000	-16,941,000	-6,979,000	-12,681,000	-43,391,000	-14,338,000	-7,596,000	-15,944,000	-79,878,000	-10,883,000	-20,172,000	-13,203,000	-28,288,000	-4,836,000	-2,156,000	-15,923,000	-6,028,000	-6,724,000	-20,611,000	-4,630,000	-2,029,000	-9,248,000	-10,221,000	-2,411,000	-4,326,000	-2,401,000	-19,653,000	-17,195,000	-12,156,000	-2,581,000	-1,636,000	-16,119,000	-10,021,000	-8,215,000	-1,773,000	-3,318,000	-13,998,000	-3,791,000	-37,643,000	-1,365,000	-7,014,000	-6,427,000	-2,737,000	-1,546,000	-7,276,000	-2,545,000	-2,099,000	-12,142,000	-16,493,000	-872,000	-10,461,000	-1,386,000	-521,000	-9,265,000	-3,962,000	-1,106,000	-706,000	-1,552,000	-8,858,000	-1,903,000	-10,083,000	-4,032,000	-1,786,000	-18,127,000	-1,756,000	-1,867,000	-2,334,000
proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance costs							0	-9,000
proceeds from term loan											0	0
payment of deferred financing costs											0	0
net increase in cash and cash equivalents			-75,597,000	4,048,000	-19,379,000	-20,535,000			128,133,000	1,011,000					9,379,000	-1,231,000	2,482,000	-14,981,000	2,789,000	-13,426,000	-45,996,000	66,003,000	-4,308,000	-7,003,000			-8,873,000	5,093,000	7,335,000	-2,120,000	4,515,000	-2,824,000	-4,912,000	5,107,000	5,023,000	-5,429,000	1,247,000	3,428,000	-1,585,000	286,000								-1,387,000													-2,897,000	-1,113,000	-642,000	968,000	960,000	1,080,000	-1,124,000	1,221,000	-1,590,000	-2,402,000	-1,125,000	2,141,000	859,000
liabilities assumed associated with a purchase of a business
notes payable related to the purchase of non-controlling interest, permanent equity							0
issuance of restricted stock related to purchase of business
gain on sale of fixed assets																																						-19,000
others
increase in accounts payable and accrued expenses				6,484,000							-3,187,000			1,445,000	128,000	8,201,000	-7,641,000	3,969,000	-1,068,000	9,017,000	2,451,000	2,027,000	-3,769,000	4,340,000	-5,054,000	274,000	-4,866,000	4,897,000	-2,544,000	7,389,000	-1,147,000	3,083,000	-272,000	5,315,000	-2,184,000	-2,537,000	3,393,000	4,322,000														-3,728,000	2,684,000			685,000	-956,000				-939,000				-647,000			-240,000	-225,000			1,526,000	1,313,000
proceeds on sale of redeemable non-controlling interest, temporary equity															0	37,000			73,000	35,000
purchase of interest in businesses - seller financing portion				6,440,000	455,000	500,000
initial contingent consideration related to purchase of interest of businesses
notes payable related to purchase of non-controlling interest, permanent equity											-280,000
proceeds on sale of partnership interest - redeemable non-controlling interest									130,000	107,000
proceeds on sale of fixed assets																				423,000	-295,000	316,000	0	-1,000	6,000	59,000	-1,000	1,000			14,000	5,000	0	62,000	19,000	0	0	42,000																							4,000	21,000	22,000	10,000	10,000	15,000	71,000	12,000	-16,000	29,000	2,000	6,000
deferred payments related to purchase of interest in business
fair market value of initial contingent consideration related to purchase of interest of businesses
decrease (increase) in other long-term liabilities
payment of medicare accelerated and advance funds																		-14,054,000
purchase of non controlling interest-permanent equity								-223,000
net decrease in cash and cash equivalents											-6,320,000	-10,658,000	24,343,000	-4,338,000												-3,130,000
earnings in unconsolidated affiliate									-326,000	-274,000	-192,000	-304,000	-340,000	-339,000
decrease in other assets																		221,000																						106,000			805,000	735,000		-2,719,000	1,772,000	2,095,000				38,000				355,000
increase (decrease ) in accounts payable and accrued expenses
proceeds on sales of redeemable non-controlling interest-temporary												57,000
proceeds from revolving line of credit									17,000,000	7,000,000	40,000,000	0	26,000,000	35,000,000	123,000,000	65,000,000	68,000,000	60,000,000	80,000,000	35,000,000	11,000,000	88,000,000	35,000,000	30,000,000	61,000,000	19,000,000	24,000,000	24,000,000	36,000,000	19,000,000	30,000,000	14,000,000	17,000,000	32,000,000	40,000,000	35,000,000	44,000,000	49,000,000	17,000,000	34,000,000	22,000,000	35,300,000	48,000,000	29,000,000	62,350,000	25,900,000	31,950,000	30,600,000	24,000,000	23,500,000	24,000,000	8,400,000	24,900,000	51,700,000	38,300,000	4,000,000	9,500,000	9,000,000	8,300,000	19,500,000	7,000,000	6,500,000	5,250,000	5,700,000	8,600,000	0	9,500,000	2,800,000	0
payments on revolving line of credit											-9,000,000	0	-144,000,000	-31,000,000	-42,000,000	-70,000,000	-46,000,000	-60,000,000	-71,000,000	-61,000,000	-92,000,000	-20,000,000	-40,000,000	-41,000,000	-28,000,000	-28,000,000	-40,000,000	-26,000,000	-22,000,000	-31,000,000	-32,000,000	-27,000,000	-6,000,000	-20,000,000	-30,000,000	-41,500,000	-54,000,000	-40,500,000	-17,500,000	-27,000,000	-34,000,000	-33,800,000	-48,500,000	-23,500,000	-36,500,000	-27,500,000	-36,600,000	-27,600,000	-22,700,000	-27,400,000	-28,200,000	-7,700,000	-27,800,000	-41,100,000	-27,300,000	-4,700,000	-4,000,000	-12,600,000	-15,600,000	-9,000,000	-10,000,000	-13,700,000	-7,250,000	-4,500,000
payment on term loan
notes receivable related to sale of partnership interest - redeemable non-controlling interest									2,155,000	532,000	0	104,000						287,000					0	90,000
deferred income taxes										221,000	-1,768,000	1,770,000	2,175,000	2,132,000	4,396,000	-1,868,000	979,000	2,181,000	576,000	903,000	-368,000	-1,369,000	971,000	-1,741,000	3,303,000	2,118,000	7,912,000	-1,363,000	-574,000	-1,162,000																																				-108,000	64,000	343,000		-142,000	21,000	81,000	471,000
increase in other assets										1,897,000	-7,609,000	1,439,000	965,000	-735,000	-438,000	60,000						2,846,000	866,000	15,000	-1,865,000	-894,000			1,098,000	-1,238,000		1,555,000			3,580,000	-2,536,000	-161,000	-2,282,000			-690,000												55,000	-776,000										-144,000	384,000	546,000	-1,039,000	-148,000	208,000	24,000	4,000	-396,000	-107,000
(decrease ) increase in accounts payable and accrued expenses										-1,846,000
decrease in other long-term liabilities										-1,359,000				-2,480,000
purchase of non controlling interest-permanent
net income including non-controlling interest and earnings from unconsolidated affiliates											3,348,000	12,821,000	15,256,000	11,982,000
gain on sale of partnership interest																		96,000	0				309,000
derecognition (write-off) of goodwill - closed clinics
(gain) loss on sale of clinics and fixed assets											0	-29,000
impairment of goodwill
purchase of non-controlling interest, permanent equity											0	-124,000	-57,000	-99,000	-181,000				-54,000	-40,000			-290,000	0
sales of partnership interest, clinics and fixed assets
sale of non-controlling interest - permanent
(payment) receipt of medicare accelerated and advance funds															0	0
notes receivable related to sale of partnership interest
unrealized gain on cash flow hedge
proceeds on sales of partnership interest, clinics and fixed assets												0	736,000	4,000	139,000	304,000
loss on revaluation of put-right liability
purchase of businesses - contingent consideration
notes payable due to purchase of non-controlling interest, permanent equity													0	296,000
gain on revaluation of put-right liability														-603,000
sales of non-controlling interest-permanent															0
interest															157,000	454,000	443,000	298,000	0	258,000	595,000	349,000	478,000	510,000	559,000	343,000	652,000	599,000	580,000	526,000	497,000	1,512,000	-495,000	599,000	14,000	258,000	264,000	248,000	225,000	235,000	246,000	200,000	312,000	345,000	0	115,000	118,000	119,000	101,000	116,000	139,000	283,000	10,000	127,000	95,000	93,000	40,000	24,000			56,000	173,000	90,000	5,000	82,000	198,000	104,000	100,000	197,000	16,000	21,000	29,000	11,000
purchase of business - payable to common shareholders of acquired business																							0	0
note receivables related to sale of partnership interest																627,000
short swing profit settlement
purchase of redeemable non-controlling interest - notes payable																				0
receivables related to sale of partnership interest
net income including non-controlling interests																	17,472,000	11,886,000	18,627,000	15,763,000	14,763,000	3,338,000	12,015,000	13,069,000	19,800,000	12,375,000	13,673,000	11,879,000	13,236,000	10,054,000	8,706,000	6,594,000	6,390,000	6,034,000	556,000	7,972,000	10,060,000	7,680,000	9,117,000	6,151,000	7,263,000	7,418,000	9,420,000	6,323,000
adjustments to reconcile net income including non-controlling interests to net cash provided byoperating activities:
decrease in accounts receivable - other																																					10,000	43,000		125,000				146,000
distributions to non-controlling interests, permanent and temporary equity																	-4,133,000	-5,265,000	-4,108,000	-8,516,000	-3,366,000	-2,341,000	-5,373,000	-2,928,000	-5,358,000	-2,576,000	-5,176,000	-3,735,000
purchase of businesses - payable
adjustments to reconcile net income including non-controlling interests to net cash from operating activities:
purchase of redeemable non-controlling interest - temporary equity
proceeds on sales of partnership interest and clinics																		152,000		0
payable related to purchase of redeemable non-controlling interest, temporary equity																		4,829,000
write-off of goodwill - closed clinics																			0	0	0	1,859,000
decrease (increase) in patient accounts receivable																			-3,218,000	-4,763,000
decrease(increase) in accounts receivable - other																			931,000	447,000
decrease (increase) in other assets																			-1,243,000	-565,000							112,000							757,000																170,000							111,000			741,000
payments to settle mandatorily redeemable non-controlling interests																											0	0	0	-265,000	-131,000	0	0	-2,230,000
medicare accelerated and advance payment funds																			1,130,000	63,000
notes receivables related to sale of partnership interest																			324,000	284,000
benefit from doubtful accounts																				1,279,000	739,000	1,361,000	1,450,000	962,000	1,240,000	1,206,000	1,501,000	890,000	1,151,000	1,061,000	956,000	930,000	888,000	898,000	1,078,000	917,000	956,000	1,089,000	1,061,000	991,000	1,018,000	1,090,000	1,054,000	950,000	1,007,000	1,095,000	1,193,000	1,089,000	1,192,000	1,259,000	1,280,000	1,117,000	1,231,000	1,426,000	504,000	624,000	778,000	695,000	734,000	1,034,000	772,000	1,001,000	869,000	706,000	843,000	747,000	735,000	748,000	813,000	691,000	501,000	631,000	566,000
payable due to purchase of redeemable non-controlling interest																				0
gain on sale of partnership interest, net of tax
increase in other liabilities																					106,000	239,000	-577,000				-1,956,000	2,660,000	173,000	-845,000	170,000	209,000	1,000	76,000	-356,000	261,000	82,000	365,000					220,000	184,000	195,000	645,000	-37,000	56,000	-1,340,000	-12,000	43,000	-12,000	-882,000	192,000	207,000	208,000	575,000	168,000	106,000	-45,000	961,000	-20,000	-584,000	58,000	234,000	51,000	117,000	68,000	126,000	-23,000	242,000	-7,000	187,000
payable related to purchase of partnership interest - settlement of redeemable non-controlling interest
purchase of non-controlling interest - payable
gain on derecognition of debt
increase in mandatorily redeemable non-controlling interests																															4,510,000	668,000	3,490,000	2,911,000
purchase of majority interest in businesses																							-232,000
sales of non-controlling interest-permanent equity
proceeds on sale of partnership interest																							0
decrease in other liabilities																									-438,000	-263,000
purchase of business																																																																				-2,831,000
purchase of business - seller financing portion																									3,772,000	228,000	0	400,000	400,000	150,000	500,000	0	750,000	900,000	486,000	14,000	0	500,000	850,000	500,000	0	0					400,000	400,000
receivable related to sale of partnership interest
purchase of redeemable non-controlling interest																										-2,053,000
purchase of non-controlling interest																										-139,000		-27,000	1,000	-246,000
purchase of businesses, net of cash acquired																											-64,000	-7,185,000	-8,357,000	-761,000	-2,942,000	-75,000	-17,995,000	-15,670,000	-10,665,000	0	-59,000	-12,899,000	-8,022,000	-6,445,000	-30,000	-1,490,000	-10,625,000	-125,000	-36,500,000	-130,000	-5,783,000	-4,215,000	-527,000	-222,000	-6,090,000	-1,090,000	-1,302,000				-9,351,000	32,000	-93,000	-8,785,000					-8,042,000	-103,000
(purchase) sale of non-controlling interest
acquisition of non-controlling interest - seller financing portion																																			-113,000	-14,000	0	514,000
payment to settle redeemable non-controlling interest - financing portion
receivable from sale of non-controlling interests
loss on sale and disposal of fixed assets
net (cash used in) provided by financing activities																													2,466,000	-15,240,000
distributions to non-controlling interests																														-2,208,000	-1,874,000	-1,033,000	-1,728,000	-937,000	2,553,000	-3,067,000	-3,591,000	-1,613,000	-3,317,000	-1,589,000	-2,846,000	-2,085,000	-3,569,000	-1,413,000
excess tax benefit from equity-based rewards
deferred income tax																															-5,155,000	1,276,000	-735,000	-250,000	-2,709,000	1,518,000	1,461,000	2,709,000	1,565,000	565,000	2,387,000	1,466,000	842,000	1,580,000	2,912,000	253,000	-577,000	-219,000	1,203,000	1,489,000	-564,000	1,610,000	2,401,000	482,000	585,000	365,000	-652,000	651,000	737,000	-284,000	524,000	128,000	8,000	54,000
sale of non-controlling interest, net of purchases
cash dividends paid to shareholders - funded
tax benefit from equity-based rewards
acquisitions of non-controlling interests																																			1,130,000	-414,000	138,000	-1,524,000	-609,000	-359,000	-492,000	-53,000	-2,112,000	-2,833,000
sale of non-controlling interests																																				0
tax benefit from equity-based awards																																				242,000	233,000	323,000
cash dividends to shareholders - funded																																			-2,128,000	-2,128,000	-2,129,000	-2,125,000
excess tax benefit from equity-based awards
revaluation of redeemable non-controlling interests																																									0	0	202,000	1,639,000
excess tax benefit from exercise of equity-based awards																																						-323,000
(gain) loss on sale or abandonment of assets
excess tax benefit from shared-based compensation																																							-159,000	-271,000
increase in other long term liabilities																																							262,000	665,000
cash dividends to shareholders																																									-1,474,000	-1,467,000			-1,210,000	-1,210,000	-1,211,000	-1,207,000	-5,834,000	-1,066,000	-1,059,000	-1,058,000	-946,000	-953,000
payment of notes payable																																							-408,000	-200,000	-250,000	0	-325,000	-250,000	0	-225,000	-184,000	-50,000	-150,000	-100,000			-150,000	0	0	-100,000	-279,000	-258,000			-353,000	-405,000	-548,000	-73,000	-124,000	-434,000	-215,000	-114,000	-167,000	-115,000	-140,000	-166,000	-68,000
tax benefit from share-based compensation																																							159,000	271,000
cash - end of period																																							-1,585,000	14,557,000		2,890,000	-3,827,000	16,761,000
loss on sale of business and sale or abandonment of assets																																								17,000		-14,000	15,000	19,000
write-off of goodwill - closed clinic																																								34,000
(decrease) in accounts payable and accrued expenses																																								-5,976,000
proceeds on sale of business and fixed assets																																								8,000	4,000	5,000	22,000	16,000				14,000
loss on sale of business and fixed assets																																																14,000
excess tax benefit from exercise of stock options																																									-422,000	-311,000	-89,000	-126,000																	0
tax benefit from stock options exercised																																																33,000
excess tax benefit from stock options exercised																																										311,000	89,000	126,000		244,000				197,000	126,000	58,000		180,000	227,000	395,000	288,000	36,000	4,000	8,000	0				0	50,000	3,000	75,000	7,000	68,000	100,000	9,000	10,000
proceeds from exercise of stock options																																										28,000				2,000				67,000	12,000	3,000		0	1,000	1,000	16,000	316,000	81,000	7,000	0				0	402,000	28,000	65,000	126,000	69,000	145,000	228,000	11,000
net increase in cash																																										2,890,000	-3,827,000	3,863,000								457,000		483,000	-1,674,000	1,487,000		2,544,000	-4,295,000	5,042,000
cash - beginning of period																																										0	0	12,898,000
balance december 31, 2013																																										0	0	14,316,000
issuance of restricted stock, net of cancellations																																										29,000	21,000	97,000
compensation expense - restricted stock
excess tax benefit of equity grants
revaluation of redeemable non-controlling interests, net of tax
reclass to redeemable non- controlling interests
acquisition of non-controlling interests
dividends paid to shareholders
contributions of non-controlling interest partner
distributions to non-controlling interest partners
net income																																																																	2,233,000	2,531,000	2,855,000	2,385,000	2,486,000	2,120,000	2,303,000	1,829,000	1,484,000
balance september 30, 2014
dividends payable to shareholders
distributions to noncontrolling interest partners
balance june 30, 2014
balance march 31, 2014																																												14,413,000
net income including noncontrolling interests																																															7,374,000	5,609,000	5,794,000	6,298,000	7,314,000	6,812,000	10,142,000	5,853,000	7,603,000	6,185,000	6,358,000	6,177,000	7,034,000	5,131,000	4,207,000	5,140,000	6,034,000	4,593,000
adjustments to reconcile net income including noncontrolling interests to net cash from operating activities:
gain on purchase price settlement
gain on sale of business and fixed assets
acquisitions of noncontrolling interests																																																-956,000	-930,000	-349,000	-400,000	-565,000	-1,504,000	-3,050,000	-15,870,000	-15,000	-129,000	-338,000	-198,000	-17,000	-2,194,000
sale of noncontrolling interests																																																	0	0
settlement of purchase price
distributions to noncontrolling interests																																															-2,816,000	-1,594,000	-2,482,000	-2,099,000	-2,832,000	-1,919,000	-2,485,000	-2,685,000	-2,608,000	-1,989,000	-2,344,000	-2,405,000	-2,594,000	-2,237,000	-2,009,000	-2,329,000	-2,707,000	-2,393,000
purchase and retire of common stock																																																													0	0	-2,939,000	-2,647,000
acquisition of noncontrolling interest - seller financing portion
increase in accounts receivable—other																																																				-426,000
acquisitions of non-controlling interests, net of sales
net proceeds on sale of non controlling interest, fixed assets and business
cash—beginning of period																																																				9,983,000
cash—end of period																																																				10,440,000
purchase of business—seller financing portion																																																				100,000
balance december 31, 2012																																														0
issuance of restricted stock																																														0				0	23,000	58,000		58,000	32,000	70,000		71,000
compensation expense—restricted stock
transfer of compensation liability for certain stock issued pursuant to incentive plans
purchases of business
balance september 30, 2013
loss on sale or abandonment of assets																																																		46,000	25,000	58,000									19,000	72,000	4,000	27,000	83,000	51,000	68,000	45,000	81,000	14,000	16,000	6,000
acquisitions of noncontrolling interests, net of sales
net proceeds on sale of fixed assets and business																																																		30,000	22,000	6,000		1,000	1,000	3,000		2,000	770,000	125,000
net decrease in cash
acquisition of non controlling interests
balance june 30, 2013
cash and cash equivalents—beginning of period
cash and cash equivalents—end of period
acquisition of noncontrolling interest—seller financing portion
increase in accounts receivable — other																																																					287,000	-165,000	-703,000	-409,000	-128,000	65,000	-172,000	-62,000									-75,000	6,000	-191,000	173,000
purchase and retirement of common stock
cash — beginning of period																																																						0	0	9,179,000		0	0	6,429,000
cash — end of period																																																						483,000	-1,674,000	10,666,000		2,544,000	-4,295,000	11,471,000
purchase of business — seller financing portion																																																					0				250,000	50,000	0	225,000					556,000	0			0
acquisition of noncontrolling interest — seller financing portion																																																					0	0
balance december 31, 2011																																																		0	0	13,919,000
compensation expense — restricted stock
contribution of non controlling interests partners
sale of non controlling interests
cash dividends to uspt shareholders
balance september 30, 2012
balance june 30, 2012
balance march 31, 2012																																																				13,980,000
cash and cash equivalents — beginning of period																																																													0	0	0	10,113,000		0	0	7,976,000		0	0	10,952,000
cash and cash equivalents — end of period																																																													-2,897,000	-1,113,000	-642,000	11,081,000		1,080,000	-1,124,000	9,197,000		-2,402,000	-1,125,000	13,093,000
(gain) loss on sale of business and sale or abandonment of assets																																																						65,000	19,000	56,000		58,000	150,000	-558,000
balance december 31, 2010																																																						0	0	13,893,000
cancellation of restricted stock																																																						0				0
purchase and retirement of treasury stock
tax benefit from exercise of stock options																																																																		-50,000	-3,000	-75,000		-68,000	-100,000	-9,000
transfer of compensation liability for certain stock issued pursuant to long-term incentive plans
purchase of noncontrolling interests, net of tax
balance september 30, 2011
balance june 30, 2011
cash dividend to shareholders																																																								-943,000
transfer of compensation expense liability for certain stock issued pursuant to long-term incentive plan
balance march 31, 2011																																																								14,011,000
recognition of deferred rent subsidies																																																													-130,000	-124,000	-121,000	-117,000	-108,000	-105,000	-122,000	-96,000	-105,000	-109,000	-112,000	-130,000	-103,000
balance december 31, 2009																																																										0	0	13,829,000
compensation expense — stock options
sale of business
purchase and retirement of treasury shares
purchase of noncontrolling interests
balance september 30, 2010
balance june 30, 2010
balance march 31, 2010																																																												13,829,000
(increase) in other assets
purchase of marketable securities — available for sale																																																																					0	0	-440,000	-1,600,000
proceeds on sale of marketable securities — available for sale																																																																					0	1,900,000	0	640,000
purchase of business — issuance of common stock
write-off of goodwill																																																																	-39,000
decrease in accounts receivable — other																																																														1,000	-6,000	197,000				130,000
cash paid during the period for :
adjustments to reconcile net income to net cash from operating activities:
minority interests in earnings of subsidiary limited partnerships																																																																	1,853,000	1,583,000	1,977,000	1,672,000	1,576,000	1,369,000	1,467,000	1,315,000	1,201,000
acquisitions of minority interests, included in goodwill
distributions to minority investors in subsidiary limited partnerships																																																																	-2,058,000	-1,848,000	-1,916,000	-1,473,000	-1,387,000	-1,605,000	-1,196,000	-1,463,000	-881,000
repurchase of common stock																																																																									-860,000
cash and cash equivalents — beginning of year
cash and cash equivalents — end of year
increase in patient account receivable																																																																		880,000	-682,000	-2,755,000		-1,175,000	-956,000	-1,001,000
decrease (increase) in accounts receivable – other
acquisitions of minority interest, included in goodwill																																																																		-739,000	-372,000	-285,000		-383,000	0	-129,000
payment on revolving line of credit																																																																		-6,000,000
changes in operating assets and liabilites:
decrease (increase) in accounts receivable — other
purchase of business, net of cash acquired																																																																					-576,000
closure costs — write-off of goodwill
gain on sale or abandonment of assets
impairment charge — goodwill
non-cash transactions during the period:
conversion of series c notes into common stock
adjustments to reconcile net income to net cash from
operating activities:
loss on sale or abandonment of fixed assets																																																																									12,000
increase in accounts receivable -- other																																																																									-137,000
acquisition of minority interests, included in goodwill																																																																									-800,000
cash and cash equivalents -- beginning of period																																																																									15,002,000
gain on sale or abandonment of fixed assets
acquisition of businesses
note payable purchase of minority interest purchase of business — seller financing portion

We provide you with 20 years of cash flow statements for U.S. Physical Therapy stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of U.S. Physical Therapy stock. Explore the full financial landscape of U.S. Physical Therapy stock with our expertly curated income statements.

The information provided in this report about U.S. Physical Therapy stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.